{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T13:25:17Z","timestamp":1790083517774,"version":"4.0.1"},"reference-count":85,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T00:00:00Z","timestamp":1698883200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Respiratory syncytial virus (RSV) infection and shingles are two viral diseases that affect older adults, and a combined vaccine to protect against both could be beneficial. RSV infection causes hospitalisations and significant morbidity in both children and adults and can be fatal in the elderly. The RSV fusion (F) envelope glycoprotein induces a strong RSV-neutralising antibody response and is the target of protective immunity in the first RSV vaccine for older adults, recently approved by the FDA. An initial childhood infection with the varicella zoster virus (VZV) results in chickenpox disease, but reactivation in older adults can cause shingles. This reactivation in sensory and autonomic neurons is characterized by a skin-blistering rash that can be accompanied by prolonged pain. The approved protein-in-adjuvant shingles vaccine induces VZV glycoprotein E (gE)-fspecific antibody and CD4+ T cell responses and is highly effective. Here we report the evaluation of RSV\/shingles combination vaccine candidates based on non-replicating chimpanzee adenovirus (ChAd) vectors. We confirmed the cellular and humoral immunogenicity of the vaccine vectors in mice using T cell and antibody assays. We also carried out an RSV challenge study in cotton rats which demonstrated protective efficacy following a homologous prime-boost regimen with our preferred vaccine candidate.<\/jats:p>","DOI":"10.3390\/vaccines11111679","type":"journal-article","created":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T09:16:21Z","timestamp":1698916581000},"page":"1679","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Pre-Clinical Development of an Adenovirus Vector Based RSV and Shingles Vaccine Candidate"],"prefix":"10.3390","volume":"11","author":[{"given":"Lawrence","family":"Petherbridge","sequence":"first","affiliation":[{"name":"Vaccitech Ltd., Harwell OX11 0DF, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Davis","sequence":"additional","affiliation":[{"name":"Vaccitech Ltd., Harwell OX11 0DF, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Robinson","sequence":"additional","affiliation":[{"name":"Vaccitech Ltd., Harwell OX11 0DF, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Evans","sequence":"additional","affiliation":[{"name":"Vaccitech Ltd., Harwell OX11 0DF, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Sebastian","sequence":"additional","affiliation":[{"name":"Vaccitech Ltd., Harwell OX11 0DF, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,11,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e13145","DOI":"10.1111\/irv.13145","article-title":"Incidence, Hospitalization, and Mortality in Children Aged 5\u2009Years and Younger with Respiratory Syncytial Virus-Related Diseases: A Systematic Review and Meta-Analysis","volume":"17","author":"Duan","year":"2023","journal-title":"Influ. Other Respir. Viruses"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa043951","article-title":"Respiratory Syncytial Virus Infection in Elderly and High-Risk Adults","volume":"352","author":"Falsey","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"S577","DOI":"10.1093\/infdis\/jiz059","article-title":"Global Disease Burden Estimates of Respiratory Syncytial Virus-Associated Acute Respiratory Infection in Older Adults in 2015: A Systematic Review and Meta-Analysis","volume":"222","author":"Shi","year":"2020","journal-title":"J. Infect. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/irv.12912","article-title":"Cost Determinants among Adults Hospitalized with Respiratory Syncytial Virus in the United States, 2017\u20132019","volume":"16","author":"Choi","year":"2022","journal-title":"Influ. Other Respir. Viruses"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Amand, C., Tong, S., Kieffer, A., and Kyaw, M.H. (2018). Healthcare Resource Use and Economic Burden Attributable to Respiratory Syncytial Virus in the United States: A Claims Database Analysis. BMC Health Serv. Res., 18.","DOI":"10.1186\/s12913-018-3066-1"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Prasad, N., Newbern, E.C., Trenholme, A.A., Thompson, M.G., McArthur, C., Wong, C.A., Jelley, L., Aminisani, N., Huang, Q.S., and Grant, C.C. (2020). The Health and Economic Burden of Respiratory Syncytial Virus Associated Hospitalizations in Adults. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0234235"},{"key":"ref_7","first-page":"753","article-title":"Incidence and Economic Burden of Respiratory Syncytial Virus among Adults in the United States: A Retrospective Analysis Using 2 Insurance Claims Databases","volume":"28","author":"Rossi","year":"2022","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1056\/NEJMoa2209604","article-title":"Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults","volume":"388","author":"Papi","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_9","unstructured":"Commissioner, O. (2023, July 14). of the FDA Approves First Respiratory Syncytial Virus (RSV) Vaccine, Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-respiratory-syncytial-virus-rsv-vaccine."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1056\/NEJMoa2116154","article-title":"Vaccine Efficacy in Adults in a Respiratory Syncytial Virus Challenge Study","volume":"386","author":"Zareba","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1056\/NEJMoa2213836","article-title":"Efficacy and Safety of a Bivalent RSV Prefusion F Vaccine in Older Adults","volume":"388","author":"Walsh","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1016\/j.vaccine.2020.01.055","article-title":"Safety and Immunogenicity of Novel Modified Vaccinia Ankara-Vectored RSV Vaccine: A Randomized Phase I Clinical Trial","volume":"38","author":"Samy","year":"2020","journal-title":"Vaccine"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1093\/infdis\/jiaa460","article-title":"Broad Antibody and Cellular Immune Response from a Phase 2 Clinical Trial with a Novel Multivalent Poxvirus-Based Respiratory Syncytial Virus Vaccine","volume":"223","author":"Jordan","year":"2021","journal-title":"J. Infect. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"841471","DOI":"10.3389\/fimmu.2022.841471","article-title":"A Recombinant MVA-Based RSV Vaccine Induces T-Cell and Antibody Responses that Cooperate in the Protection against RSV Infection","volume":"13","author":"Endt","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_15","unstructured":"Bavarian Nordic (2022). A Phase 2a, Randomised, Double-Blinded, Placebo-Controlled Study to Assess the Safety, Immunogenicity and Efficacy of the Recombinant MVA-BN\u00ae-RSV Vaccine Against Respiratory Syncytial Virus Infection in the Virus Challenge Model in Healthy Adult Participants."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1093\/cid\/ciz653","article-title":"First-in-Human Randomized Study to Assess the Safety and Immunogenicity of an Investigational Respiratory Syncytial Virus (RSV) Vaccine Based on Chimpanzee-Adenovirus-155 Viral Vector-Expressing RSV Fusion, Nucleocapsid, and Antitermination Viral Proteins in Healthy Adults","volume":"70","author":"Cicconi","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_17","unstructured":"GlaxoSmithKline (2018). A Study to Evaluate Safety, Reactogenicity and Immunogenicity of GSK Biologicals\u2019 RSV Investigational Vaccine Based on Viral Proteins Encoded by Chimpanzee-Derived Adenovector (ChAd155-RSV) (GSK3389245A) in Healthy Adults."},{"key":"ref_18","unstructured":"GlaxoSmithKline (2021). A Phase 1\/2, Randomized, Observer-Blind, Controlled, Multi-Center, Dose-Escalation Study to Evaluate Safety, Reactogenicity and Immunogenicity of GSK Biologicals\u2019 Respiratory Syncytial Virus (RSV) Investigational Vaccine Based on the RSV Viral Proteins F, N and M2-1 Encoded by Chimpanzee-Derived Adenovector (ChAd155-RSV) (GSK3389245A), When Administered Intramuscularly According to a 0, 1-Month Schedule to RSV-Seropositive Infants Aged 12 to 23 Months."},{"key":"ref_19","first-page":"1293","article-title":"Safety and Immunogenicity of a ChAd155-Vectored RSV Vaccine (ChAd155-RSV) in Healthy RSV-Seropositive Children 12\u201323 Months of Age","volume":"227","author":"Epalza","year":"2022","journal-title":"J. Infect. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1056\/NEJMoa2207566","article-title":"Efficacy and Safety of an Ad26.RSV.preF-RSV preF Protein Vaccine in Older Adults","volume":"388","author":"Falsey","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_21","unstructured":"Janssen Vaccines & Prevention, B.V. (2023). A Randomized, Double-Blind, Placebo-Controlled Phase 3 Efficacy Study of an Ad26.RSV.preF-Based Vaccine in the Prevention of Lower Respiratory Tract Disease Caused by RSV in Adults Aged 60 Years and Older."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/d41573-023-00085-x","article-title":"RSV Vaccines Score Landmark FDA Approvals","volume":"22","author":"Kingwell","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_23","unstructured":"(2023, March 16). Moderna Announces mRNA-1345, an Investigational Respiratory Syncytial Virus (RSV) Vaccine, Has Met Primary Efficacy Endpoints in Phase 3 Trial in Older Adults. Available online: https:\/\/investors.modernatx.com\/news\/news-details\/2023\/Moderna-Announces-mRNA-1345-an-Investigational-Respiratory-Syncytial-Virus-RSV-Vaccine-Has-Met-Primary-Efficacy-Endpoints-in-Phase-3-Trial-in-Older-Adults\/default.aspx."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.cger.2007.03.003","article-title":"Herpes Zoster and Postherpetic Neuralgia in Older Adults","volume":"23","author":"Schmader","year":"2007","journal-title":"Clin. Geriatr. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"25151355221084535","DOI":"10.1177\/25151355221084535","article-title":"Global Herpes Zoster Incidence, Burden of Disease, and Vaccine Availability: A Narrative Review","volume":"10","author":"Pan","year":"2022","journal-title":"Ther. Adv. Vaccines Immunother."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1097\/j.pain.0000000000001718","article-title":"Aggregate Health and Economic Burden of Herpes Zoster in the United States: Illustrative Example of a Pain Condition","volume":"161","author":"Harvey","year":"2020","journal-title":"Pain"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Gater, A., Uhart, M., McCool, R., and Pr\u00e9aud, E. (2015). The Humanistic, Economic and Societal Burden of Herpes Zoster in Europe: A Critical Review. BMC Public Health, 15.","DOI":"10.1186\/s12889-015-1514-y"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1086\/605611","article-title":"Varicella-Zoster Virus-Specific Immune Responses to Herpes Zoster in Elderly Participants in a Trial of a Clinically Effective Zoster Vaccine","volume":"200","author":"Weinberg","year":"2009","journal-title":"J. Infect. Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1172\/JCI109739","article-title":"Cellular and Humoral Immunity in the Pathogenesis of Recurrent Herpes Viral Infections in Patients with Lymphoma","volume":"65","author":"Arvin","year":"1980","journal-title":"J. Clin. Investig."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1086\/651199","article-title":"Influence of Age and Nature of Primary Infection on Varicella-Zoster Virus-Specific Cell-Mediated Immune Responses","volume":"201","author":"Weinberg","year":"2010","journal-title":"J. Infect. Dis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1007\/s40520-019-01374-5","article-title":"Vaccination for Quality of Life: Herpes-Zoster Vaccines","volume":"33","author":"Lang","year":"2021","journal-title":"Aging Clin. Exp. Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.coviro.2013.04.004","article-title":"T-Cell Immunity to Human Alphaherpesviruses","volume":"3","author":"Ouwendijk","year":"2013","journal-title":"Curr. Opin. Virol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1086\/528696","article-title":"Varicella-Zoster Virus-Specific Immune Responses in Elderly Recipients of a Herpes Zoster Vaccine","volume":"197","author":"Levin","year":"2008","journal-title":"J. Infect. Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1080\/21645515.2018.1560918","article-title":"Immune Responses to Zoster Vaccines","volume":"15","author":"Levin","year":"2019","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/82_2021_245","article-title":"Immune Responses to Varicella-Zoster Virus Vaccines","volume":"Volume 438","author":"Arvin","year":"2021","journal-title":"Varicella-Zoster Virus"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1080\/14760584.2021.1956906","article-title":"A Practitioner\u2019s Guide to the Recombinant Zoster Vaccine: Review of National Vaccination Recommendations","volume":"20","author":"Parikh","year":"2021","journal-title":"Expert. Rev. Vaccines"},{"key":"ref_37","first-page":"1033","article-title":"A Live Varicella Vaccine Used for Children in Hospitals","volume":"24","author":"Takahashi","year":"1978","journal-title":"IARC Sci. Publ. (1971)"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1080\/14760584.2016.1213632","article-title":"Adjuvant System AS01: Helping to Overcome the Challenges of Modern Vaccines","volume":"16","author":"Didierlaurent","year":"2017","journal-title":"Expert. Rev. Vaccines"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1093\/cid\/ciz770","article-title":"Adjuvanted Recombinant Glycoprotein E Herpes Zoster Vaccine","volume":"70","author":"Levin","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_40","unstructured":"(2023, June 08). SK bioscience. Available online: https:\/\/www.skbioscience.com\/en\/news\/news_01_01?mode=view&id=162."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/S2666-7568(22)00039-3","article-title":"Post-Licensure Zoster Vaccine Effectiveness against Herpes Zoster and Postherpetic Neuralgia in Older Adults: A Systematic Review and Meta-Analysis","volume":"3","author":"Mbinta","year":"2022","journal-title":"Lancet Healthy Longev."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2896","DOI":"10.1016\/j.vaccine.2019.04.014","article-title":"The Comparative Efficacy and Safety of Herpes Zoster Vaccines: A Network Meta-Analysis","volume":"37","author":"McGirr","year":"2019","journal-title":"Vaccine"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1093\/aje\/kwx245","article-title":"Long-Term Effectiveness of the Live Zoster Vaccine in Preventing Shingles: A Cohort Study","volume":"187","author":"Baxter","year":"2018","journal-title":"Am. J. Epidemiol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"ofac485","DOI":"10.1093\/ofid\/ofac485","article-title":"Long-Term Protection against Herpes Zoster by the Adjuvanted Recombinant Zoster Vaccine: Interim Efficacy, Immunogenicity, and Safety Results up to 10 Years after Initial Vaccination","volume":"9","author":"Strezova","year":"2022","journal-title":"Open Forum Infect. Dis."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1093\/gerona\/gly218","article-title":"The Impact of Reactogenicity After the First Dose of Recombinant Zoster Vaccine on the Physical Functioning and Quality of Life of Older Adults: An Open-Label, Phase III Trial","volume":"74","author":"Schmader","year":"2019","journal-title":"J. Gerontol. A Biol. Sci. Med. Sci."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1080\/21645515.2020.1741312","article-title":"Post Hoc Analysis of Reactogenicity Trends between Dose 1 and Dose 2 of the Adjuvanted Recombinant Zoster Vaccine in Two Parallel Randomized Trials","volume":"16","author":"Colindres","year":"2020","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"25151355211057479","DOI":"10.1177\/25151355211057479","article-title":"Safety and Reactogenicity of the Adjuvanted Recombinant Zoster Vaccine: Experience from Clinical Trials and Post-Marketing Surveillance","volume":"9","author":"Fiore","year":"2021","journal-title":"Ther. Adv. Vaccines Immunother."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/nchem.1963","article-title":"Development of a Minimal Saponin Vaccine Adjuvant Based on QS-21","volume":"6","author":"Chea","year":"2014","journal-title":"Nat. Chem."},{"key":"ref_49","unstructured":"(2023, August 04). GSK Pricing Information and Details|GSKForYou. Available online: https:\/\/www.gskforyou.com\/gsk-pricing-information\/."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.1080\/21645515.2017.1383575","article-title":"Chimpanzee Adenoviral Vectors as Vaccines for Outbreak Pathogens","volume":"13","author":"Ewer","year":"2017","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/bit.27945","article-title":"Manufacturing a Chimpanzee Adenovirus-Vectored SARS-CoV-2 Vaccine to Meet Global Needs","volume":"119","author":"Joe","year":"2022","journal-title":"Biotechnol. Bioeng."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1146\/annurev-med-043021-015237","article-title":"SARS-CoV-2 Vaccination-Induced Thrombotic Thrombocytopenia: A Rare but Serious Immunologic Complication","volume":"74","author":"Abrams","year":"2023","journal-title":"Annu. Rev. Med."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Dicks, M.D.J., Spencer, A.J., Edwards, N.J., Wadell, G., Bojang, K., Gilbert, S.C., Hill, A.V.S., and Cottingham, M.G. (2012). A Novel Chimpanzee Adenovirus Vector with Low Human Seroprevalence: Improved Systems for Vector Derivation and Comparative Immunogenicity. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0040385"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Folegatti, P.M., Bellamy, D., Roberts, R., Powlson, J., Edwards, N.J., Mair, C.F., Bowyer, G., Poulton, I., Mitton, C.H., and Green, N. (2019). Safety and Immunogenicity of a Novel Recombinant Simian Adenovirus ChAdOx2 as a Vectored Vaccine. Vaccines, 7.","DOI":"10.3390\/vaccines7020040"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"e663","DOI":"10.1016\/S2666-5247(22)00126-4","article-title":"Safety and Immunogenicity of a Simian-Adenovirus-Vectored Rabies Vaccine: An Open-Label, Non-Randomised, Dose-Escalation, First-in-Human, Single-Centre, Phase 1 Clinical Trial","volume":"3","author":"Jenkin","year":"2022","journal-title":"Lancet Microbe"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"6951","DOI":"10.1016\/j.vaccine.2019.04.056","article-title":"Simian Adenovirus Vector Production for Early-Phase Clinical Trials: A Simple Method Applicable to Multiple Serotypes and Using Entirely Disposable Product-Contact Components","volume":"37","author":"Fedosyuk","year":"2019","journal-title":"Vaccine"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41541-023-00674-2","article-title":"Lyophilization to Enable Distribution of ChAdOx1 and ChAdOx2 Adenovirus-Vectored Vaccines without Refrigeration","volume":"8","author":"Zhang","year":"2023","journal-title":"NPJ Vaccines"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1038\/nsmb.3267","article-title":"Iterative Structure-Based Improvement of a Fusion-Glycoprotein Vaccine against RSV","volume":"23","author":"Joyce","year":"2016","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1126\/science.1243283","article-title":"Structure-Based Design of a Fusion Glycoprotein Vaccine for Respiratory Syncytial Virus","volume":"342","author":"McLellan","year":"2013","journal-title":"Science"},{"key":"ref_60","unstructured":"(2022, December 09). gE\u2014Envelope Glycoprotein E\u2014Varicella-Zoster Virus (Strain Oka Vaccine) (HHV-3) | UniProtKB | UniProt. Available online: https:\/\/www.uniprot.org\/uniprotkb\/Q9J3M8\/entry."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1080\/19420862.2015.1008351","article-title":"Cleavage Efficient 2A Peptides for High Level Monoclonal Antibody Expression in CHO Cells","volume":"7","author":"Chng","year":"2015","journal-title":"MAbs"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2175558","DOI":"10.1080\/21645515.2023.2175558","article-title":"Preclinical Immunogenicity of an Adenovirus-Vectored Vaccine for Herpes Zoster","volume":"19","author":"Ulaszewska","year":"2023","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"e005398","DOI":"10.1136\/jitc-2022-005398","article-title":"Intravenous Administration of Viral Vectors Expressing Prostate Cancer Antigens Enhances the Magnitude and Functionality of CD8+ T Cell Responses","volume":"10","author":"Vardeu","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1126\/science.aav9033","article-title":"A Proof of Concept for Structure-Based Vaccine Design Targeting RSV in Humans","volume":"365","author":"Crank","year":"2019","journal-title":"Science"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.virusres.2019.04.006","article-title":"Characterization of the Role of N-Glycosylation Sites in the Respiratory Syncytial Virus Fusion Protein in Virus Replication, Syncytium Formation and Antigenicity","volume":"266","author":"Leemans","year":"2019","journal-title":"Virus Res."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/s41591-020-01179-4","article-title":"Phase 1\/2 Trial of SARS-CoV-2 Vaccine ChAdOx1 nCoV-19 with a Booster Dose Induces Multifunctional Antibody Responses","volume":"27","author":"Barrett","year":"2021","journal-title":"Nat. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.biologicals.2009.02.017","article-title":"The Cotton Rat Model of Respiratory Viral Infections","volume":"37","author":"Boukhvalova","year":"2009","journal-title":"Biologicals"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"5371","DOI":"10.1016\/j.vaccine.2015.08.071","article-title":"Maternal Transfer of RSV Immunity in Cotton Rats Vaccinated during Pregnancy","volume":"33","author":"Blanco","year":"2015","journal-title":"Vaccine"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1093\/oxfordjournals.aje.a120955","article-title":"Respiratory Syncytial Virus Disease in Infants despite Prior Administration of Antigenic Inactivated Vaccine","volume":"89","author":"Kim","year":"1969","journal-title":"Am. J. Epidemiol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1038\/s41591-021-01449-9","article-title":"Immune Responses against SARS-CoV-2 Variants after Heterologous and Homologous ChAdOx1 nCoV-19\/BNT162b2 Vaccination","volume":"27","author":"Hammerschmidt","year":"2021","journal-title":"Nat. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"579872","DOI":"10.3389\/fimmu.2020.579872","article-title":"Innate Immune Responses to Chimpanzee Adenovirus Vector 155 Vaccination in Mice and Monkeys","volume":"11","author":"Collignon","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"S48","DOI":"10.1093\/infdis\/166.Supplement_1.S48","article-title":"Animal Models of Varicella","volume":"166","author":"Myers","year":"1992","journal-title":"J. Infect. Dis."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Laemmle, L., Goldstein, R.S., and Kinchington, P.R. (2019). Modeling Varicella Zoster Virus Persistence and Reactivation\u2014Closer to Resolving a Perplexing Persistent State. Front. Microbiol., 10.","DOI":"10.3389\/fmicb.2019.01634"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.chom.2021.11.006","article-title":"Upper and Lower Respiratory Tract Correlates of Protection against Respiratory Syncytial Virus Following Vaccination of Nonhuman Primates","volume":"30","author":"Zohar","year":"2022","journal-title":"Cell Host Microbe"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1016\/S0140-6736(20)32466-1","article-title":"Safety and Immunogenicity of ChAdOx1 nCoV-19 Vaccine Administered in a Prime-Boost Regimen in Young and Old Adults (COV002): A Single-Blind, Randomised, Controlled, Phase 2\/3 Trial","volume":"396","author":"Ramasamy","year":"2021","journal-title":"Lancet"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41541-022-00566-x","article-title":"Anti-Ad26 Humoral Immunity Does Not Compromise SARS-CoV-2 Neutralizing Antibody Responses Following Gam-COVID-Vac Booster Vaccination","volume":"7","author":"Byazrova","year":"2022","journal-title":"NPJ Vaccines"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/S0140-6736(22)00770-X","article-title":"Safety and Immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) Vaccine in Children Aged 6\u201317 Years: A Preliminary Report of COV006, a Phase 2 Single-Blind, Randomised, Controlled Trial","volume":"399","author":"Li","year":"2022","journal-title":"Lancet"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S0140-6736(21)00432-3","article-title":"Single-Dose Administration and the Influence of the Timing of the Booster Dose on Immunogenicity and Efficacy of ChAdOx1 nCoV-19 (AZD1222) Vaccine: A Pooled Analysis of Four Randomised Trials","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/S0140-6736(21)00628-0","article-title":"Efficacy of ChAdOx1 nCoV-19 (AZD1222) Vaccine against SARS-CoV-2 Variant of Concern 202012\/01 (B.1.1.7): An Exploratory Analysis of a Randomised Controlled Trial","volume":"397","author":"Emary","year":"2021","journal-title":"Lancet"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1021\/acs.accounts.6b00242","article-title":"Development of Improved Vaccine Adjuvants Based on the Saponin Natural Product QS-21 through Chemical Synthesis","volume":"49","author":"Tan","year":"2016","journal-title":"Acc. Chem. Res."},{"key":"ref_81","unstructured":"(2023, August 25). EMA Vaxzevria (Previously COVID-19 Vaccine AstraZeneca). Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/vaxzevria."},{"key":"ref_82","unstructured":"(2023, August 25). Shingrix | European Medicines Agency. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/shingrix."},{"key":"ref_83","unstructured":"(2023, August 23). CDC Shingles Vaccination Is the Best Way to Help Protect Yourself, Available online: https:\/\/www.cdc.gov\/vaccines\/vpd\/shingles\/public\/shingrix\/index.html."},{"key":"ref_84","unstructured":"(2023, August 25). Summary of the Public Assessment Report (PAR) for Vaxzevria\u2014Last Updated 03\/23\u2014GOV.UK, Available online: https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/1148800\/CMA_UKPAR_COVID_19_Vaccine_AstraZeneca_PAR_PAR_update_Annex_I.pdf."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1080\/21645515.2021.1879579","article-title":"Early Examination of Real-World Uptake and Second-Dose Completion of Recombinant Zoster Vaccine in the United States from October 2017 to September 2019","volume":"17","author":"Patterson","year":"2021","journal-title":"Hum. Vaccin. Immunother."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/11\/11\/1679\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:16:03Z","timestamp":1760130963000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/11\/11\/1679"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,2]]},"references-count":85,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,11]]}},"alternative-id":["vaccines11111679"],"URL":"https:\/\/doi.org\/10.3390\/vaccines11111679","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,2]]}}}